Bristol-myers Squibb Compnay

Ariad Pharmaceuticals, Inc.

Ariad Gene Therapeutics, Inc.

Universitéde Montreal

Bristol-myers Squibb

Wu Yang

Yufeng Wang

James R Corte

Donald J P Pinto

Tianan Fang

William R Ewing

Leon M Smith, Ii

Dennis Alan Holt

Paul Joseph Gilligan

Michael J Orwat

Yoon T Jeon

Terence P Keenan

Jennifer X Qiao

Ruth Richmond Wexler

Tammy C Wang

Leonard W Rozamus

Yeheng Zhu

Mimi Lifen Quan

R Michael Lawrence

Carl P Decicco

Joanne M Smallheer

Karen Anita Rossi

Jacques Y Roberge

Zilun Hu

Tao Guo

James A Johnson

Heather J Finlay

John E Lloyd

Mark E Salvati

Zulan Pi

Michael Matthew Miller

Patrick Y S Lam

Lalgudi S Harikrishnan

Ji Jiang

Peter W Glunz

Charles G Clark

Edward H Ruediger

Bang-Chi Chen

Eldon Scott Priestley

Xiaojun Zhang

Ellen K Kick

Ashvinikumar V Gavai

Dharmpal S Dodd

Rajeev S Bhide

George O Tora

Donald J Pinto

Andrew K Dilger

Kumar Balashanmuga Pabbisetty

Indawati De Lucca

Muthoni G Kamau

Edgardo Laborde

Michael Z Gilman

Timothy P Clackson

John K Dickson

Richard A Rampulla

Manoranjan Panda

Rejean Ruel

James Gillard

Timur Gungor

Carol Hui Hu

Carl Thibeault

Jeremy M Richter

Vladimir Ladziata

Scott A Shaw

Sasmita Tripathy

David P Rotella

Oz Scott Halpern

Jianqing Li

Wen Jiang

Samuel Kaye Reznik

Indawati DeLucca

Cheryl A Digits

Leon M Smith

Michael S Bowsher

John Kenneth Dickson, Jr

Christopher Blair Cooper

Zheming Ruan

Hannguang J Chao

Alexandre L'Heureux

Roy J Vaz

Kamalraj Thiyagarajan

Huji Tuerdi

Sheldon Hiebert

Michael R Lawrence

Dora M Schnur

Donald Jp Pinto

Ruel Rejean

Donald JP Pinto

Leon M Smith Ii

Leon M Ii Smith

Patrick YS Lam

Donald JP Pinto Pinto

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Pyrimidinones as factor XIA inhibitors

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocycles as factor xia inhibitors

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Biarylmethyl heterocycles

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or &#x3b2;-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Macrocycles as factor XIA inhibitors

The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Spiroheptane salicylamides and related compounds as inhibitors of ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. 

Tricyclic rho kinase inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. 

Spiroheptane salicylamides and related compounds as inhibitors of rock

Macrocycles as factor XIa inhibitors

Pyrimidinones as factor XIa inhibitors

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocyclic factor XIa inhibitors bearing heterocyclic groups

The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

The present invention provides compounds of Formula (V):  or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Dihydropyridone P1 as factor XIa inhibitors

Growing community of inventors

Princeton Junction, NJ, United States of America

Wu Yang